Left Atrial Appendage Closure Device

Now FDA approved! The WATCHMAN Left Atrial Appendage Closure Device is a first-of-its-kind, proven alternative to long-term warfarin therapy for stroke risk reduction in patients with non-valvular atrial fibrillation.

Key Resources

Indications, Safety & Warnings Physician Resources Information for Patients Reimbursement Resources

Product Details

See More


The WATCHMAN Device is intended for percutaneous, transcatheter closure of the left atrial appendage (LAA). Patients with non-valvular atrial fibrillation who are at increased risk for stroke and systemic embolism, are suitable for warfarin and seek a non-pharmacologic alternative to warfarin may be eligible for a WATCHMAN Device. By closing off the LAA, the risk of stroke may be reduced and, over time, patients may be able to stop taking warfarin.

Proximal Face
Intra-LAA Design
Nitinol Frame

The WATCHMAN LAAC Device is designed specifically for the left atrial appendage. Featuring an intra-LAA design to avoid contact with the left atrial wall, the WATCHMAN Device is engineered to:

  • Conform to the unique anatomy of the LAA to reduce embolization risk
  • Minimize the surface area facing the left atrium to reduce the risk of post-implant thrombus formation

Learn more about the device

Patient Experiences

Hear AF patients discuss how the WATCHMAN Device has changed their lives.

Physician Testimonials

Dr. Vivek Reddy describes how the WATCHMAN Device impacts his AF patients.

History of Clinical Leadership